Positive phase IIb data for BAF312 (siponimod) in MS

If it's on your mind and it has to do with multiple sclerosis in any way, post it here.

Positive phase IIb data for BAF312 (siponimod) in MS

Postby MSUK » Fri Apr 20, 2012 3:35 am

Image

At the 64th annual meeting of the American Academy of Neurology (AAN) Novartis will present the key results from a phase II dose finding study of its investigational compound BAF312 (siponimod), a selective modulator of the S1P receptor subtypes 1 and 5 (S1P1, 5-R modulator), in MS.

This double-blind placebo-controlled study applied an innovative adaptive trial design to optimally describe the dose response relationship.

A statistically significant dose response relationship could be established....Read More - http://www.msrc.co.uk/index.cfm/fuseact ... ageid/1397
MS-UK - http://www.ms-uk.org/
User avatar
MSUK
Family Elder
 
Posts: 2180
Joined: Wed Oct 14, 2009 3:00 pm

Advertisement

Return to General Discussion

 


  • Related topics
    Replies
    Views
    Last post

Who is online

Users browsing this forum: silverbelle990


Contact us | Terms of Service